Vivus' EvaMist Gets FDA ApprovalMonday July 30, 8:41 am ET...

  1. 92 Posts.
    Vivus' EvaMist Gets FDA Approval
    Monday July 30, 8:41 am ET
    Licensee KV Pharmaceutical's Says Vivus' Menopause Drug EvaMist Approved in the U.S.


    NEW YORK (AP) -- KV Pharmaceutical Co. and Vivus Inc. said Monday the Food and Drug Administration approved Vivus' EvaMist for symptoms associated with menopause.
    St. Louis-based KV Pharmaceutical licensed U.S. marketing rights to the drug from Mountain View, Calif.-based Vivus in March. Vivus is eligible to receive a $140 million cash payment upon approval of the drug. The deal also calls for two separate milestone payments of up to $30 million. Those payments are based on annual sales levels.

    EvaMist is expected to be launched during the second half of KV Pharmaceutical's fiscal year 2008.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.6¢
Change
0.000(0.00%)
Mkt cap ! $6.524M
Open High Low Value Volume
1.5¢ 1.6¢ 1.5¢ $9.887K 624.5K

Buyers (Bids)

No. Vol. Price($)
1 6355 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 20000 1
View Market Depth
Last trade - 15.00pm 26/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.